Acromegaly is rated under diagnostic code 7908: 30 percent for enlargement of acral parts or long bone overgrowth with an enlarged sella turcica, 60 percent with arthropathy, glucose intolerance, and hypertension, and 100 percent with evidence of increased intracranial pressure such as visual field loss, plus arthropathy, glucose intolerance, and either hypertension or cardiomegaly.
Addison's disease is rated under diagnostic code 7911 at 20, 40, or 60 percent based on crisis frequency and the need for continuous corticosteroid therapy.
Cushing's syndrome is rated under diagnostic code 7907 at 10, 30, 60, or 100 percent based on symptom severity and treatment requirements.
Diabetes insipidus is rated under diagnostic code 7909: 30 percent for the first three months after the initial diagnosis, and 10 percent afterward when there is persistent polyuria or the condition requires continuous hormonal therapy such as desmopressin. Ratings beyond that come from documenting residuals and complications under the body systems they affect.
Type 1 diabetes is rated under diagnostic code 7913 at 10, 20, 40, 60, or 100 percent based on management requirements and complications.
Type II diabetes is rated under diagnostic code 7913 at 10, 20, 40, 60, or 100 percent based on treatment requirements and complications.
Hashimoto's thyroiditis is rated as hypothyroidism (DC 7903) at 30 percent for six months after diagnosis (100 percent for myxedema); after that, residuals are rated under the affected body system.
Hyperaldosteronism is rated under diagnostic code 7917, which has no percentage tiers of its own: VA evaluates it as a malignant or benign neoplasm, as appropriate. A malignant tumor rates 100 percent under diagnostic code 7914 during treatment; the far more common benign adenoma is rated on its residuals, chiefly hypertension under diagnostic code 7101 and any documented effects of low potassium.
Hyperparathyroidism is rated under diagnostic code 7905 at 10 or 100 percent based on whether the condition is active or in remission after surgical removal.
Hyperthyroidism (including Graves' disease, DC 7900) is rated at 30 percent for six months after diagnosis; after that, residuals and complications of treatment are rated under the body system each affects.
Hypogonadism has no diagnostic code of its own. VA typically rates it by analogy under a built up code such as 7599-7523, borrowing the criteria for complete testicular atrophy: 0 percent for one testis and 20 percent for both. Most of the real compensation comes from elsewhere: special monthly compensation under subsection (k) for loss of use of a creative organ, and separate ratings for documented consequences such as erectile dysfunction, osteoporosis, or depression.
Hypopituitarism has no fixed percentage table. VA rates it under the polyglandular syndrome instruction, diagnostic code 7912, which directs raters to evaluate according to the major manifestations: each hormone deficiency is rated under the diagnostic code for the body system it affects, and the ratings are combined.
Thyroid disease (hypothyroidism, DC 7903) is rated at 30 percent for six months after diagnosis (100 percent for myxedema); after that, residuals are rated under the affected body system.
Hypothyroidism is rated under DC 7903 at 30 percent for six months after diagnosis (100 percent for myxedema); after that, VA rates the residuals under the body system each affects.
Pituitary adenoma is rated under diagnostic code 7917 by analogy to other endocrine tumors based on functional status, hormone production, and treatment.